An Arizona Psilocybin Research Advisory Council will meet for the first time on Tuesday to start the process of providing millions of dollars in grant funding to support research into the therapeutic potential of psychedelic mushrooms.
The council—which was established under the Arizona Department of Health Services (ADHS) as part of large-scale budget legislation that the governor signed in May—is meeting about a month before officials plan to open an application period for potential grant recipients.
The legislature has appropriated $5 million for psilocybin research, focused on clinical trials that are meant to identify therapeutic applications that could receive federal Food and Drug Administration (FDA) approval for the treatment of 13 listed conditions—including post-traumatic stress disorder (PTSD), depression, anxiety, long COVID symptoms and substance misuse disorder.
John Garcia, program director of the Arizona Biomedical Research Centre (ABRC) under ADHS, said in a notice last week that the division plans to begin soliciting grant applications in approximately one month.
“Any clinical trials that are funded pursuant to this announcement and subsequent grant solicitation shall prioritize: using whole mushroom psilocybin cultivated under a Schedule I license for research, issued by the United States Drug Enforcement Administration; and using veterans, first responders, frontline
Read full article on Marijuana Moment
